Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer
About this study
This is a prospective, randomised, controlled, multicentre study to evaluate the efficacy and safety of continuous versus intermittent pyrotinib therapy in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer.
- Condition
- Advanced Breast Cancer
- Tested
- Pyrotinib
- Sponsor
- Wenjin Yin
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 9
- Minimum age: 18 years
- Study condition: Advanced Breast Cancer
- Ageā„18 years old
- Pathologically confirmed advanced or locally advanced breast cancer not amenable to curative surgery
- Pathologically confirmed HER2+ at least once for either primary or metastatic lesion
- Previously treated with any number of lines for advanced disease and eligible for a pyrotinib-containing regimen at the discretion of physician
- At least one measurable lesion or bone-only disease (osteolytic or mixed) according to RECIST v1.1
- ECOG 0-1
- Adequate organ function
Exclusion 2
- During pregnancy and lactation
- Difficulties with pyrotinib administration or absorption
Where
1 site, 1 recruiting
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, China
Contact
-
Wenjin Yin, M.D.
86(21)68385569 yinwenjin@renji.com
-
Yin
Potential match only. Final eligibility is determined by the study team.